Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Exploring the interaction of alpha-synuclein and LUC7l in Parkinson's Disease

EF 2023-24

Résumé
Parkinson’s Disease (PD) is a life-altering disorder for which there is currently no cure. Patients typically experience unintentional and uncontrollable movements due to the degeneration of brain regions which are important for motor control. Available treatments focus solely on mitigating symptoms since the mechanisms underlying PD development are yet to be fully understood. A key player in conceptualizing the development of PD is the protein alpha-synuclein (?Syn) which is encoded by the SNCA gene. An abnormal buildup of ?Syn is observed in almost all PD patients and mutations in the SNCA gene cause rare genetic forms of the disease. Despite these instrumental findings, the exact role that ?Syn plays in PD including how ?Syn may be toxic to cells in the brain remains unclear. Growing evidence suggests that a contributing factor may be the accumulation of ?Syn in a specific cell compartment called the nucleus. To explore the role of nuclear ?Syn, our lab identified neighbouring proteins of ?Syn in the nucleus that may mediate its toxicity. This project will explore one of the top identified proteins called LUC7l. The aims of this study are to characterize the interaction between ?Syn and LUC7l as well as explore the functional interplay between the two proteins. Results will prompt future work to investigate whether the ?Syn-LUC7l interaction can be modified to rescue the observed toxic effects of nuclear ?Syn in PD. This knowledge will enhance our understanding of how nuclear ?Syn contributes to toxicity as well as inform the development of treatments for PD which target such effects.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505898
Name
Brain Devin M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the interaction of alpha-synuclein and LUC7l in Parkinson's Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha-Synuclein; Neurodegeneration; Protein-Protein Interactions
Abstract
Parkinson’s Disease (PD) is a life-altering disorder for which there is currently no cure. Patients typically experience unintentional and uncontrollable movements due to the degeneration of brain regions which are important for motor control. Available treatments focus solely on mitigating symptoms since the mechanisms underlying PD development are yet to be fully understood. A key player in conceptualizing the development of PD is the protein alpha-synuclein (?Syn) which is encoded by the SNCA gene. An abnormal buildup of ?Syn is observed in almost all PD patients and mutations in the SNCA gene cause rare genetic forms of the disease. Despite these instrumental findings, the exact role that ?Syn plays in PD including how ?Syn may be toxic to cells in the brain remains unclear. Growing evidence suggests that a contributing factor may be the accumulation of ?Syn in a specific cell compartment called the nucleus. To explore the role of nuclear ?Syn, our lab identified neighbouring proteins of ?Syn in the nucleus that may mediate its toxicity. This project will explore one of the top identified proteins called LUC7l. The aims of this study are to characterize the interaction between ?Syn and LUC7l as well as explore the functional interplay between the two proteins. Results will prompt future work to investigate whether the ?Syn-LUC7l interaction can be modified to rescue the observed toxic effects of nuclear ?Syn in PD. This knowledge will enhance our understanding of how nuclear ?Syn contributes to toxicity as well as inform the development of treatments for PD which target such effects.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brain, Devin M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~